BI 224436

Research use only, not for human use.

BI 224436 is a potent, specific, noncatalytic site integrase inhibitor (NCINI) of HIV-1 with EC50 of 11-27 nM against different HIV-1 laboratory strains.

BI 224436 is a potent, specific, noncatalytic site integrase inhibitor (NCINI) of HIV-1 with EC50 of 11-27 nM against different HIV-1 laboratory strains, with minimal cellular cytotoxicity; exhibits a low, ～2.1-fold decrease in antiviral potency in the presence of 50% human serum andserum-shifted EC95 values ranging between 22 and 75 nM; also retains full antiviral activity against recombinant viruses encoding INSTI resistance substitutions N155S, Q148H, and E92Q; displays an additive effect in combination with most approved antiretrovirals, including INSTIs.HIV Infection Phase 1 Clinical

BI224436

Microbiology/Virology

HIV

HIV

Infection

HIV Infection

1155419-89-8

391.47

C24H25NO4

>98% (HPLC)

DMSO : ≥ 50 mg/mL 112.99 mM

O=C(O)[C@H](C1=C(C2=CC(CCCO3)=C3C=C2)C4=CC=CC=C4N=C1)OC(C)(C)C

(2S)-[4-(3,4-Dihydro-2H-chromen-6-yl)-3-quinolinyl][(2-methyl-2-propanyl)oxy]acetic acid

(-20℃)

With Ice Pack

≥ 2 years